The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IQV | -4.57% | +30.09% | +5.4% | +417% |
| S&P | +14.5% | +93.32% | +14.09% | +312% |
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.02B | 5.3% |
| Gross Profit | $1.05B | -1.1% |
| Gross Margin | 26.03% | -1.7% |
| Market Cap | $27.26B | -29.2% |
| Market Cap / Employee | $0.30M | -30.8% |
| Employees | 90K | 2.3% |
| Net Income | $266.00M | -26.7% |
| EBITDA | $812.00M | -0.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.04B | 32.0% |
| Accounts Receivable | $3.34B | 2.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.39B | 17.1% |
| Short Term Debt | $1.31B | 12.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.50% | -0.9% |
| Return On Invested Capital | 5.31% | 1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $292.00M | -34.4% |
| Operating Free Cash Flow | $443.00M | -24.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 31.08 | 26.21 | 24.03 | 22.83 | -16.76% |
| Price to Book | 6.43 | 5.12 | 5.12 | 4.59 | -24.41% |
| Price to Sales | 2.85 | 2.31 | 2.02 | 1.74 | -32.34% |
| Price to Tangible Book Value | -3.49 | -2.78 | -2.36 | -2.02 | -32.23% |
| Price to Free Cash Flow TTM | 22.26 | 16.81 | 14.46 | 13.58 | -36.33% |
| Enterprise Value to EBITDA | 65.23 | 52.07 | 55.45 | 50.26 | -19.07% |
| Free Cash Flow Yield | 4.5% | 6.0% | 6.9% | 7.4% | 57.07% |
| Return on Equity | 22.0% | 22.5% | 21.7% | 19.8% | -13.28% |
| Total Debt | $13.70B | $14.48B | $14.51B | $15.70B | 16.73% |
IQV earnings call for the period ending June 30, 2022.
IQV earnings call for the period ending March 31, 2022.
IQV earnings call for the period ending December 31, 2021.
IQV earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
